Loading...
For more than 10 years, thiazolidinediones (TZDs) have been prescribed for diabetes therapy in the U.S. on the sole basis of evidence that they improve glycemic control. An association of TZDs with heart failure is relatively well-established; however, recent data have implicated rosiglitazone in other adverse cardiovascular events as well.
Two new studies further address the risks of rosiglitazone. In an observational cohort study, 227,571 Medicare patients (median age, 74.4) began therapy with either rosiglitazone or pioglitazone between July 2006 and June 2009. During a median follow-up of 105 days, rosiglitazone recipients were significantly more likely than pioglitazone recipients to experience adverse events including stroke (hazard ra…